Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Journal of Immunology (Baltimore, Md. : 1950)|June 14, 2019
TRAILshort Protects against CD4 T Cell Death during Acute HIV InfectionSekar Natesampillai, Ana C Paim, Nathan W Cummins, et al.The Analyst|July 3, 2023
Optimizing single cell proteomics using trapped ion mobility spectrometry for label-free experimentsDong-Gi Mun, Firdous A Bhat, Husheng Ding, et al.AIDS (London, England)|June 1, 2019
HIV elite control is associated with reduced TRAILshort expressionAna C Paim, Nathan W Cummins, Sekar Natesampillai, et al.Plos Pathogens|October 19, 2020
Reactivating latent HIV with PKC agonists induces resistance to apoptosis and is associated with phosphorylation and activation of BCL2Andrea J French, Sekar Natesampillai, Ashton Krogman, et al.Journal of Virology|April 13, 2018
HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the ProteasomeSekar Natesampillai, Nathan W Cummins, Zilin Nie, et al.The Journal of Biological Chemistry|August 24, 2011
Isolation of a TRAIL antagonist from the serum of HIV-infected patientsDavid J Schnepple, Brett Shepard, Gary D Bren, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2017
Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the MicroenvironmentZilin Nie, Fatma Aboulnasr, Sekar Natesampillai, et al.Journal of Virology|February 5, 2016
Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir SizeNathan W Cummins, Amy M Sainski, Haiming Dai, et al.AIDS (London, England)|November 8, 2017
An advanced BLT-humanized mouse model for extended HIV-1 cure studiesKerry J Lavender, Craig Pace, Kathrin Sutter, et al.The Journal of Cell Biology|September 24, 2014
Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activationAmy M Sainski, Haiming Dai, Sekar Natesampillai, et al.Pageof 3